Transforming Large B-Cell Lymphoma (LBCL): CAR T and Novel Agents - Episode 11

ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL

A dive into the latest results from the ZUMA-1 study, evaluating axicabtagene ciloleucel (axi-cel) in relapsed/refractory LBCL.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Understanding LBCL: Presentation, Diagnosis, and Prognostic Indicators
    EP. 2: Large B-Cell Lymphoma: Treatment Approaches and Evolving Therapies
    EP. 3: Advancing Lymphoma Treatments: CAR T-Cell and Bispecific Therapies
    EP. 4: CAR T-Cell Therapy’s Impact on Lymphoma Management
    EP. 5: Real-World Use of CAR T-Cell Therapy in Patients with Lymphoma
    EP. 6: Challenges in CAR T-Cell Therapy for Lymphoma
    EP. 7: Exploring LBCL: Transplant Eligibility and Second Line Treatment Selection of Novel Agents
    EP. 8: CAR T: A Review of Clinical Data for Second Line Treatments of Large B-Cell Lymphoma
    EP. 9: Approaches to Treatment Sequencing in LBCL
    EP. 10: Innovations in Immunotherapy: CAR T-Cells, Allogeneic Approaches, and Bispecifics
    Now Viewing
    EP. 11: ZUMA-1: Axi-Cel in Relapsed/Refractory LBCL
    EP. 12: Lisocabtagene Maraleucel: A Review of TRANSCEND NHL 001 in R/R LBCL
    EP. 13: Observations in Progression Post-CAR T for Lymphoma
    EP. 14: Emerging Bispecifics in the Treatment Paradigm for R/R LBCL
    EP. 15: Future Perspectives in Large B-Cell Lymphoma
    x